Administration of curcumin in advanced CRC patients inhibits lipopolysaccharide (LPS)-induced PGE2 [280], decrease in malondialdehyde-DNA M1G adduct (MDA) and reduce COX-2 level in colorectal cancer tissues [281]. The gene discussed is PTGS2; the disease is colorectal cancer.